Business Wire - The global leader in news distribution
Updated: 45 min 38 sec ago
Ontario Bioscience Innovation Organization Announces a Call for Applications for the 2019 Capital Access Advisory Program (CAAP®)
TORONTO--(BUSINESS WIRE)--#healthscience--The Ontario Bioscience Innovation Organization (OBIO®), the leading advocate for Ontario’s health science industry, is pleased to announce a call for applications for the 2019 OBIO Capital Access Advisory Program (CAAP®). OBIO CAAP is a unique, industry-led initiative that provides selected high-potential Ontario health science companies with mentoring, strategic guidance and access to an expansive network of health science industry experts and investors to enhance the
TORONTO--(BUSINESS WIRE)--Recordati Rare Diseases Canada Inc. today announced the commercial launch of PANHEMATIN®, for treatment of acute intermittent porphyria (AIP).
Global Digital Scent Technology Market Outlook (2017-2026): A $3.11 Trillion Opportunity - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Digital Scent Technology - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering. According to this report, the Global Digital Scent Technology market accounted for $320.24 billion in 2017 and is expected to reach $3,115.15 billion by 2026 growing at a CAGR of 28.8% during the forecast period. Widespread use of digital scent technology in defense and security, demand for e-nose application for diagnosis in the medical industr
VANCOUVER, British Columbia--(BUSINESS WIRE)--#3Dprinting--Biotech company Aspect Biosystems has received a $2.7 million investment from the Government of Canada’s Western Innovation (WINN) Initiative.
HOUSTON--(BUSINESS WIRE)--#celltherapy--SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using its universal donor product, CybroCell™, today announced that a single injection of modified human dermal fibroblasts (HDFs), resulted in significant improvements of disc height and pain reduction 12 months after injection of the cell therapy for patients with degenerative disc disease (DDD). The trial assessed patients using the Oswestry Disability Index (
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that it has revised the record and payment dates for the previously announced 20:1 common stock dividend. The Record Date for the determination of the holders of the Company’s common stock entitled to participate in the Company’s 20:1 common stock dividend will now be Tuesday, November 20, 2018. The dividend Payment Date will be Friday, No
TeamBest Companies Enters Agreement to Acquire ABT Molecular Imaging, Inc. and Announces Creation of Best ABT, Inc.
WASHINGTON & KNOXVILLE, Tenn. & VANCOUVER, British Columbia--(BUSINESS WIRE)--#ABT--TeamBest Companies enters agreement to acquire ABT Molecular Imaging, Inc. and announces creation of Best ABT, Inc.
Devonian Health Group Announces the Recognition of Sybil Dahan, President of Altius Healthcare, as Inductee into the 2018 Canadian Healthcare Marketing Hall of Fame.
QUEBEC--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, announces the recognition of Sybil Dahan, President of Altius Healthcare - commercial division of Devonian - as an inductee into the 2018 Canadian Healthcare Marketing Hall of Fame. The 2018 Annual Canadian Healthcare Hall of Fame Inductees, inc
MONTREAL--(BUSINESS WIRE)--#amorchem--Mperia Therapeutics appoints Payl Chipperton as President and CEO
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences. Wednesday, November 14, 2018, Aurinia will present a company overview at the Jefferies 2018 London Healthcare Conference in London, UK at 10:00am GMT. The presentation will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) has released its financial results for the third quarter ended September 30, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars. “We achieved a significant milestone in September with the completion of enrollment for the AURORA Phase III trial ahead of schedule. Our target enrollment of 324 patients was surpassed due to high patient demand with 358
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Stifel 2018 Healthcare Conference taking place November 13-14, 2018 in New York, NY and at the Jefferies 2018 London Healthcare Conference taking place November 14-15, 2018 in London, England. The Company will provide a corporate update at the Stifel Healthcare Conference
TORONTO--(BUSINESS WIRE)--Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), today announced that David McNally, President and CEO of the Company, will present a corporate overview at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15 at 2:00 p.m. Eastern ti
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported financial results for the third quarter ended September 30, 2018. “We continue to expand our business with our seventh pharmaceutical partner, LEO Pharma, recently entering into a strategic collaboration with Zymeworks,” said Ali Tehrani, Ph.D., Zymeworks’ President & CEO. “Importantly, this deal represents the evol
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Ag-West Bio welcomes Shawn Gibson and Danya Kordan to its board of directors. Shawn Gibson is executive director at the Agriculture Research Branch, Saskatchewan Ministry of Agriculture. Danya Kordan is Director of Research Institutes and Clusters at Innovation Saskatchewan. As the sole ‘Class A member’ of Ag-West Bio, the Government of Saskatchewan (represented by Saskatchewan Ministry of Agriculture) is entitled to elect two directors to Ag-West Bio’s
Abzena Announces 20m$ Investment into Expansion of Integrated Biotherapeutics Offering (Biologics Drug Substance and ADC) and Makes Key Executive Appointment
SAN DIEGO & BRISTOL, Pa. & CAMBRIDGE, England--(BUSINESS WIRE)--Increased biologics manufacturing capacity in San Diego, cell line development capabilities in Cambridge and synthetic chemistry services in Bristol.
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) today reported its financial results for the three and nine months ended September 30, 2018. Unless otherwise noted, all amounts are in U.S. dollars. Recent Operational and Financial Highlights Increased product revenue by 16% to $1.6 million versus $1.4 million in the same three-month period in the prior year; Closed $11 million term loan credit facility with SWK Funding LLC (“SWK”); Repaid all
MONTREAL--(BUSINESS WIRE)--#amorchem--November 6th, 2018, AmorChem is proud to be amongst the successful applicants of the Venture Capital Catalyst Initiative (“VCCI”) Stream II, announced yesterday in Montreal by the Honourable Mary Ng, federal Minister of Small Business and Export Promotion, joined by Richard Hébert, Parliamentary Secretary to the Minister of Small Business and Export Promotion. AmorChem was built through the vision and leadership of its two founders, Elizabeth Douville and Inès Holzbau
BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2018. Financial Highlights Three Months Ended (In millions, except per share amounts) September 28, September 29, 2018 2017 GAAP Revenue $ 160.8 $ 146.3 Operating Income $ 21.0 $ 12.4 Net Income Attributable to Novanta Inc. $ 14.6 $ 7.5 Diluted EPS $ 0.60 $ (0.00 ) Non
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that it has completed the second and final tranche of the acquisition of operating assets from Veneto Holdings, L.L.C. (“Veneto”), a private company, and certain of its affiliated entities (collectively, the “Veneto Group”). The Veneto Group provides specialty pharmacy services and products including surgical products and services, diagnos